CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel.

Main|Search|PHGKB




Last Posted: May 10, 2018

---

• CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel.  
  Rodríguez-González Fayna et al. Journal of clinical pharmacology 2018 May
• The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke.  
  Yi Xingyang, et al. Oncotarget 2018 4 (25) 17725-17734
• Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.  
  Roden Dan M et al. Circulation research 2018 Apr 122(9) 1176-1190
• The influence of ABCB1 and P2Y12 genetic variants on clinical outcomes in Chinese intracranial artery stenosis patients.  
  Li Xingang, et al. Clinical and experimental pharmacology & physiology 2018 4
• Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.  
  Imatoh T et al. Journal of clinical pharmacy and therapeutics 2018 Apr
• Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).  
  Bergmeijer Thomas O, et al. American heart journal 2018 4 152-159

more